Article
Construction of Escherichia coli Mutant with Decreased Endotoxic Activity by Modifying Lipid A Structure.
Marine drugs - 27 May 2015
Liu Qiong, Li Yanyan, Zhao Xinxin, Yang Xue, Liu Qing, Kong Qingke
Abstract excerpt
Escherichia coli BL21 (DE3) and its derivatives are widely used for the production of recombinant proteins, but these purified proteins are always contaminated with lipopolysaccharide (LPS). LPS is recognized by the toll-like receptor 4 and myeloid differentiation factor 2 complex of mammalian immune cells and leads to release of pro-inflammatory cytokines. It is a vital step to remove LPS from the proteins...
Topics
- Animals
- Cell Line
- Endotoxins
- Escherichia coli
- Feasibility Studies
- Humans
- Inflammation Mediators
- Interleukin-12
- Lipid A
- Lipopolysaccharides
- Mice
- Mutation